Clinical significance of serum intercellular adhesion molecule-1 detection in patients with hepatocellular carcinoma

Table 1 Concentrations of serum sICAM-1 in patients with HCC and control groups

Group	Number of patients	sICAM-1 (μg/L)a
Normal control	50	305
CH	42	462
LC	40	587
HCC	134	1801b

a median P < 0.01 vs compared with other groups;

^bP < 0.01 vs other groups each.

Table 2 Comparative analysis of serum levels of sICAM-1 and AFP in HCC patients

Group	Number of patients	sICAM-1 (μg/L)*	AFP (μg/L)*
AFP < 20 μg/L	22	1370	11
AFP 20-200 μg/L	27	1453	89
AFP > 200 μg/L	85	2018	31610

^*median.

Table 3 Ranges of serum sICAM-1 concentration in 134 patients with HCC

sICAM-1 (μg/L)	Number of patients	(%)
330-690	8	6
700-990	19	14
1000-1990	72	54
> 2000	35	26

Table 4 Serum concentrations of sICAM-1 and tumor size in 134 patients with HCC

Tumor size in diameter (cm)	sICAM-1 (μg/L)a	Number of patients
≤ 5	1518b	17
≤ 10	1769	37
> 10	1897	80

a median;

^bP > 0.05 vs others groups each.